Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08065010 · 1 trial · 1 indication
Part A
Part A
Part A
Part A
Part A
| Arm | Type | Description |
|---|---|---|
| Part A: Cohort 3: single ascending dose (SAD) | EXPERIMENTAL | Dose C - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 8: single ascending dose (SAD) | EXPERIMENTAL | Optional Japanese Cohort dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 1: single ascending dose (SAD) | EXPERIMENTAL | Dose A - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 5: single ascending dose (SAD) | EXPERIMENTAL | Dose E - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 7: single ascending dose (SAD) | EXPERIMENTAL | Dose G - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 4: single ascending dose (SAD) | EXPERIMENTAL | Dose D - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 2: single ascending dose (SAD) | EXPERIMENTAL | Dose B - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 9: single ascending dose (SAD) | EXPERIMENTAL | Optional Chinese Cohort dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 6: single ascending dose (SAD) | EXPERIMENTAL | Dose F - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 10: single ascending dose (SAD) | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 11: single ascending dose (SAD) | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 12: multiple dose | EXPERIMENTAL | Dose F - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 13: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 14: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Name | Type | Description |
|---|---|---|
| PF-08065010 | DRUG | Experimental Pfizer compound which will be subcutaneous (SC) or intravenous (IV). |
| Placebo | DRUG | Placebo which will be SC or IV |
Inclusion Criteria: * male or female between 18 and 65 years of age * deemed to be healthy Exclusion Criteria: 1. Evidence or history of clinically significant medical conditions. 2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, he...
PF-08065010 is an investigational small molecule being studied in healthy adults. It is currently in a Phase 1 clinical trial to evaluate how different amounts of the study medicine are tolerated and how it acts in the body. The drug is not approved and remains in clinical development.
PF-08065010 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 1 clinical trial to study the drug in healthy adult volunteers.
PF-08065010 is in Phase 1 clinical development. The drug is being studied in a single active trial that is currently recruiting participants. It is an investigational medicine and has not been approved for any use.
PF-08065010 is being studied in one Phase 1 clinical trial with the identifier NCT07235163. The trial is recruiting healthy adults aged 18 years and older in Belgium, with an enrollment target of 100 participants. The study is randomized, double-blind, and controlled.
PF-08065010 is a small molecule, but its specific molecular target has not been disclosed. The ongoing Phase 1 trial is designed to assess how different doses of the drug are tolerated and how it behaves in the body of healthy adults.